EUVIMEDEUVIMED entdecken
Crossref

Discovery of the 2,3-Dihydrobenzopyrane-4-one as a Potent FTO Inhibitor against Obesity-Related Metabolic Diseases

Duo Ma, Xianan Liu, Xingxing Zhang, Yaling Hong, Yumeng Wang, Famin Zhang, Leran Du, Junjie Zhao, Quan Wang, Cui Chang, Wenhu Liu, Yan Lou und 1 weitere

Journal of Medicinal Chemistry · 2025

DOI: 10.1021/acs.jmedchem.4c03124 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Medicinal Chemistry, 2025. Verfasst von Duo Ma und 12 weiteren Autor:innen. Beteiligte Einrichtung: School of Pharmacy, Inflammation and Immune Mediated Diseases Laboratory of Anhui Province, Anhui Medical University, Hefei 230032, P. R. China. Hauptthemen laut MEDLINE: Alpha-Ketoglutarate-Dependent Dioxygenase FTO, Obesity, Metabolic Diseases, Drug Discovery. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 52 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Anhui Province, School of Pharmacy, Anhui Medical University.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The involvement of the fat mass and obesity-associated gene (FTO) in the development and advancement of metabolic disorders is widely recognized. However, the existing FTO inhibitor entacapone has been limited in clinical application due to its low potency and short plasma elimination half-life. Here, through drug library screening and in depth structure-activity relationship analysis, title compound 40, eriodictyol was identified as a potent FTO inhibitor, and showed good binding to FTO by surface plasmon resonance (SPR) and Microscale thermophoresis (MST) detection. The residues Arg96, Tyr108, Ser229, Asp233, and Glu234 of FTO are essential for binding. Meanwhile, eriodictyol attenuated obesity-related metabolic diseases by enhancing glucose metabolism pathways via the FTO-FOXO1-G6PC/PCK1 axis and increasing adipose tissue heat production for weight loss via the FTO-FOXO1-Ucp1 axis in vivo. Surprisingly, eriodictyol showed good pharmacokinetic properties and no obvious toxicity. These results could provide the reference for design of new FTO inhibitors against obesity-related metabolic diseases.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Alpha-Ketoglutarate-Dependent Dioxygenase FTOObesityMetabolic DiseasesDrug DiscoveryAnti-Obesity AgentsAnimalsStructure-Activity RelationshipHumansMiceMaleMice, Inbred C57BL

Substanzen

Alpha-Ketoglutarate-Dependent Dioxygenase FTOFTO protein, humanAnti-Obesity Agents

Autor:innen und Institutionen

  • School of Pharmacy, Inflammation and Immune Mediated Diseases Laboratory of Anhui Province, Anhui Medical University, Hefei 230032, P. R. China.
  • Faculty of Science, The University of Hong Kong, Pokfulam, Kowloon, Hong Kong 999077, P. R. China.

ORCID-Profile: Xinhua Liu

Förderung

  • National Natural Science Foundation of China
  • Anhui Province
  • School of Pharmacy, Anhui Medical University

Zitieren

APA

Ma, D., Liu, X., Zhang, X., Hong, Y., Wang, Y., Zhang, F., Du, L., Zhao, J., Wang, Q., Chang, C., Liu, W., Lou, Y., & Liu, X. (2025). Discovery of the 2,3-Dihydrobenzopyrane-4-one as a Potent FTO Inhibitor against Obesity-Related Metabolic Diseases. Journal of Medicinal Chemistry. https://doi.org/10.1021/acs.jmedchem.4c03124

Vancouver

Ma D, Liu X, Zhang X, Hong Y, Wang Y, Zhang F, et al. Discovery of the 2,3-Dihydrobenzopyrane-4-one as a Potent FTO Inhibitor against Obesity-Related Metabolic Diseases. Journal of Medicinal Chemistry. 2025. doi:10.1021/acs.jmedchem.4c03124

BibTeX
@article{Ma2025,
  author = {Ma, Duo and Liu, Xianan and Zhang, Xingxing and Hong, Yaling and Wang, Yumeng and Zhang, Famin and Du, Leran and Zhao, Junjie and Wang, Quan and Chang, Cui and Liu, Wenhu and Lou, Yan and Liu, Xinhua},
  title = {Discovery of the 2,3-Dihydrobenzopyrane-4-one as a Potent FTO Inhibitor against Obesity-Related Metabolic Diseases},
  journal = {Journal of Medicinal Chemistry},
  year = {2025},
  doi = {10.1021/acs.jmedchem.4c03124}
}
Kostenlos starten →